We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.4B
AUM Growth
-$3.07B
Cap. Flow
-$3.45B
Cap. Flow %
-16.12%
Top 10 Hldgs %
34%
Holding
335
New
40
Increased
37
Reduced
44
Closed
34

Top Buys

Rank Stock Value
1
ARMK icon
Aramark
ARMK
+$209M
2
KSU
Kansas City Southern
KSU
+$193M
3
HWM icon
Howmet Aerospace
HWM
+$184M
4
MIC
Macquarie Infrastructure Holdings, LLC
MIC
+$172M
5
TMUS icon
T-Mobile US
TMUS
+$160M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.42B
2
MXIM
Maxim Integrated Products
MXIM
+$476M
3
WTW icon
Willis Towers Watson
WTW
+$468M
4
WORK
Slack Technologies, Inc.
WORK
+$462M
5
AON icon
Aon
AON
+$371M

Sector Composition

Rank Sector Weight
1 Healthcare 28.83%
2 Technology 13.3%
3 Industrials 11.55%
4 Communication Services 11.47%
5 Financials 11.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LH icon
51
Labcorp
LH
$27.3B
$100M 0.47%
+414,234
New +$104M
CYTK icon
52
Cytokinetics
CYTK
$10.7B
$97.7M 0.46%
2,732,775
-143,225
-5% -$4.22M
BPMC
53
DELISTED
Blueprint Medicines
BPMC
$97.1M 0.45%
944,403
-180,597
-16% -$16.8M
GBIO
54
DELISTED
Generation Bio
GBIO
$87.7M 0.41%
350,000
– –
KRTX
55
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$85.6M 0.4%
700,000
+70,000
+11% +$8.08M
QGEN icon
56
Qiagen
QGEN
$9.1B
$76.2M 0.36%
1,389,921
-721,932
-34% -$40.2M
RVMD icon
57
Revolution Medicines
RVMD
$44.9B
$75.7M 0.35%
2,750,000
+250,000
+10% +$7.28M
JAZZ icon
58
Jazz Pharmaceuticals
JAZZ
$16.5B
$74.9M 0.35%
+574,907
New +$86.9M
SLGC
59
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$72.2M 0.34%
+5,826,473
New +$65.7M
CRBU icon
60
Caribou Biosciences
CRBU
$178M
$70.7M 0.33%
+2,963,448
New +$72.4M
PCG icon
61
PG&E
PCG
$38.8B
$70M 0.33%
7,292,042
– –
PLYA
62
DELISTED
Playa Hotels & Resorts
PLYA
$69.2M 0.32%
8,352,553
– –
ATTO
63
DELISTED
Atento S.A.
ATTO
$62.9M 0.29%
2,230,357
– –
BABA icon
64
Alibaba
BABA
$286B
$62.4M 0.29%
421,400
-255,000
-38% -$46.4M
INFO
65
DELISTED
IHS Markit Ltd. Common Shares
INFO
$60M 0.28%
+514,900
New +$60.8M
CHNG
66
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$57.3M 0.27%
2,738,600
– –
EXAS
67
DELISTED
Exact Sciences
EXAS
$57M 0.27%
597,598
+347,598
+139% +$36.7M
IMGO
68
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$53.5M 0.25%
+2,671,313
New +$57.3M
ABBV icon
69
AbbVie
ABBV
$468B
$52M 0.24%
+481,848
New +$55.1M
PACB icon
70
Pacific Biosciences
PACB
$420M
$50.9M 0.24%
1,992,250
+1,742,250
+697% +$51.6M
ARWR icon
71
Arrowhead Research
ARWR
$12.3B
$49.7M 0.23%
796,578
+431,578
+118% +$27.9M
BRMK
72
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$48.9M 0.23%
4,956,174
-923,826
-16% -$9.6M
BIIB icon
73
Biogen
BIIB
$32B
$48.4M 0.23%
170,859
+61,859
+57% +$20.3M
PFE icon
74
CALL
Pfizer
PFE
$160B
$43M 0.2%
+1,000,000
New +$44.3M
PTGX icon
75
Protagonist Therapeutics
PTGX
$9.99B
$42.4M 0.2%
2,392,000
+62,320
+3% +$2.66M
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2021 Portfolio in Review

As of Q3 2021, Thomas Steyer held 335 positions worth $21.4B, down 13% from $24.5B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Thomas Steyer withdrew a net $3.45B in Q3 2021, closing 34 positions and reducing 44 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $1.42B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 30% a quarter earlier, followed by Technology and Industrials.

Against the trend, Thomas Steyer opened a new position in Macquarie Infrastructure Holdings, LLC worth $177M.

  • Thomas Steyer's largest Q3 2021 buy was Macquarie Infrastructure Holdings, LLC: 4,361,050 shares worth $177M.
  • Thomas Steyer added most to Aramark in Q3 2021, an estimated $209M increase.
  • Thomas Steyer's biggest Q3 2021 reduction was Willis Towers Watson, cutting an estimated $468M.
  • Thomas Steyer fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $1.42B.
  • Thomas Steyer's ten largest holdings make up 34% of its $21.4B portfolio in Q3 2021.
  • Thomas Steyer opened 40 new positions and closed 34 in Q3 2021.
  • Thomas Steyer's portfolio value fell 13% quarter-over-quarter to $21.4B.

Based on Farallon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.